At Strongbridge Biopharma, our focus on rare diseases has resulted in a portfolio of innovative treatments for rare neuromuscular and endocrine conditions, including the commercialization of KEVEYIS in the U.S.
At Strongbridge Biopharma, we are committed to delivering better results for patients, healthcare providers, employees, and investors.
The Strongbridge team is passionate about making a positive difference in the lives of patients with rare diseases. It’s why we’re here.
Learn more about this FDA-approved product for patients with a rare neuromuscular disease.
Adrenal steroidogenesis inhibitor for endogenous Cushing's syndrome is an investigational agent with a new drug application (NDA) submitted to the FDA in March 2021.